January 2017
Dear Colleague,
As we start off the new year, I’d like to share the sixth edition of the HER2-Positive Breast Cancer Updates newsletter with you.
At this time, I’d like to invite you to focus on Chapter 5 of our roundtable discussion video. This section focuses on the rationale behind the use of neoadjuvant therapy from both the medical and surgical perspectives. If you haven’t watched the full video, I encourage you to do so, as I think you’ll find it to be a valuable learning experience.
I’d also like to share some articles on such important topics as the investigative HER2-targeted dendritic cell vaccine, reducing neratinib-related toxicity, managing diarrhea in patients treated with pertuzumab, and others.
Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.
Best wishes for a happy and healthy 2017!
Heather Greene, MSN, FNP, AOCNP®
The West Cancer Center
Memphis, Tennessee
